REFERENCES
- Ototani , N. and Whistler , R. L. 1974 . Preparation and antitumor activity of 4-thio-analogues of 2,2′-anhydro-1-β-D-arabinofuranosylcytosine . J. Med. Chem. , 17 : 535 – 537 .
- Whistler , R. L. , Doner , L. W. and Nayak , U. G. 1971 . 4-Thio-D-arabinofuranosylpyrimidine nucleosides . J. Org. Chem. , 36 : 108 – 110 .
- Tiwari , K. N. , Shortnacy-Fowler , A. T. , Cappellacci , L. , Parker , W. B. , Waud , W. R. , Montgomery , J. A. and Secrist , J. A. III . 2000 . Synthesis of 4′-thio-β-D-arabinofuranosylcytosine (4′-thio-ara-C) and comparison of its anticancer activity with that of ara-C . Nucleosides Nucleotides Nucleic Acids , 19 : 329 – 340 .
- Waud , W. R. , Gilbert , K. S. , Shepherd , R. V. , Montgomery , J. A. and Secrist , J. A. III . 2003 . Preclinical antitumor activity of 4′-thio-β-D-arabinofuranosylcytosine (4′-thio-ara-C) . Cancer Chemother. Pharmacol. , 51 : 422 – 426 .
- Waud , W. R. , Gilbert , K. S. , Secrist , J. A. III , Shepherd , R. V. and Tiwari , K. N. 2004 . Preclinical antitumor activity of 4′-thio-β-D-arabinofuranosylcytosine (4′-thio-ara-C, OSI-7836) in human leukemia and lymphoma xenograft models . Proc. Amer. Assoc. Cancer Res. , 45 : 714
- Teicher , B. A. , Herman , T. S. , Holden , S. A. , Wang , Y. , Pfeffer , M. R. , Crawford , J. W. and Frei , E. III . 1990 . Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo . Science , 247 : 1457 – 1461 .
- Gish , D. T. , Kelly , R. C. , Camiener , G. W. and Wechter , W. J. 1971 . Nucleic Acids. 11. Synthesis of 5′-esters of 1-β-D-arabinofuranosylcytosine possessing antileukemic and immunosuppressive activity . J. Med. Chem. , 14 : 1159 – 1162 .
- Waud , W. R. 2004 . “ Murine L1210 and P388 leukemias ” . In Anticancer Drug Development Guide , Second edition , Edited by: Teicher , B. A. 79 – 97 . Totowa , NJ : Humana Press .
- Schabel , F. M. Jr. , Griswold , D. P. Jr. , Laster , W. R. Jr. , Corbett , T. H. and Lloyd , H. H. 1977 . Quantitative evaluation of anticancer agent activity in experimental animals . Pharmacol. Ther. [A] , 1 : 411 – 435 .
- Lloyd , H. H. 1977 . “ Application of tumor models toward the design of treatment schedules for cancer chemotherapy ” . In Growth Kinetics and Biochemical Regulation of Normal and Malignant Cells , Edited by: Drewinko , B. and Humphrey , R. M. 455 – 469 . Baltimore , MD : Williams & Wilkins .
- Waud , W. R. 2006 . “ Therapeutic resistance in leukemia ” . In Cancer Drug Resistance , Edited by: Teicher , B. A. 137 – 150 . Totowa , NJ : Humana Press .
- Someya , H. , Shaddix , S. C. , Tiwari , K. N. , Secrist , J. A. III and Parker , W. B. 2003 . Phosphorylation of 4′-thio-arabinofuranosylcytosine and its analogs by human deoxycytidine kinase . J. Pharmacol. Exp. Ther. , 304 : 1314 – 1322 .
- Parker , W. B. , Shaddix , S. C. , Rose , L. M. , Waud , W. R. , Shewach , D. S. , Tiwari , K. N. and Secrist , J. A. III . 2000 . Metabolism of 4′-thio-β-D-arabinofuranosylcytosine in CEM cells . Biochem. Pharmacol. , 60 : 1925 – 1932 .
- Brockman , R. W. 1974 . “ Mechanisms of resistance ” . In Handbook of Experimental Pharmacology. New Series. Vol. 38/1 , Edited by: Sartorelli , A. C. and Johns , D. G. 352 – 410 . New York : Springer-Verlag .
- Curt , G. A. , Clendeninn , N. J. and Chabner , B. A. 1984 . Drug resistance in cancer . Cancer Treat. Rep. , 68 : 87 – 99 .
- Cros , E. , Jordheim , L. , Dumontet , C. and Galmarini , C. M. 2004 . Problems related to resistance to cytarabine in acute myeloid leukemia . Leuk. Lymphoma , 45 : 1123 – 1132 .
- Waud , W. R. , Gilbert , K. S. and Secrist , J. A. III . 2011 . Lack of in vivo cross-resistance with 4′-thio-ara-C against drug-resistant murine P388 and L1210 leukemias . Cancer Chemother. Pharmacol. , 68 : 399 – 403 .